Literature DB >> 2403732

Hemodynamic effects of intravenous and oral sotalol.

J J Mahmarian1, M S Verani, C M Pratt.   

Abstract

Beta-adrenergic blocking agents may have negative inotropic effects that are particularly worrisome in patients with depressed cardiac function. Their membrane-stabilizing properties may be a contributing factor. Sotalol is currently thought not to cause significant myocardial depression. Intravenous sotalol administration has minimal effects on resting stroke volume, although heart rate and consequently cardiac output are significantly decreased. Systolic blood pressure decreases, with a minimal change in diastolic or mean pressure. Hemodynamic effects are usually seen within 15 to 20 minutes of administration. Hemodynamic indexes are maintained even in patients with mildly depressed ejection fractions (mean ejection fraction of 43 +/- 15%) after oral sotalol administration. Although heart rate decreases, cardiac index is unchanged because of a significant increase in stroke volume index. The latter results from an increase in preload (secondary to bradycardia) and a decrease in afterload. Sotalol is well tolerated, although occasionally it may cause worsening heart failure. This is seen in patients with markedly depressed left ventricular function and inadequate cardiac reserve characterized by an inability to increase stroke volume and cardiac output with exercise. Long-term (1-year) patient follow-up reveals no significant hemodynamic deterioration from initial values obtained after oral administration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403732     DOI: 10.1016/0002-9149(90)90198-a

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

Review 1.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

2.  Early experience with intravenous sotalol in children with and without congenital heart disease.

Authors:  Santiago O Valdés; Christina Y Miyake; Mary C Niu; Caridad M de la Uz; S Yukiko Asaki; Andrew P Landstrom; Andrew E Schneider; Craig G Rusin; Raajen Patel; Wilson W Lam; Jeffrey J Kim
Journal:  Heart Rhythm       Date:  2018-07-10       Impact factor: 6.343

Review 3.  Intravenous Sotalol - Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal.

Authors:  Syeda Atiqa Batul; Rakesh Gopinathannair
Journal:  J Atr Fibrillation       Date:  2017-02-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.